LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways

Brigatinib (BGB) is a newly approved anaplastic lymphoma kinase (ALK) inhibitor. On April 28, 2017, BGB was approved by the U.S. FDA for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. The toxicity profile of BGB includes nausea, fatigue, diarrhea, elevate...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadi, Adnan A., Attwa, Mohamed W., Darwish, Hany W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2018
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077137/
https://www.ncbi.nlm.nih.gov/pubmed/35540908
http://dx.doi.org/10.1039/c7ra10533a

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077137/
https://www.ncbi.nlm.nih.gov/pubmed/35540908
http://dx.doi.org/10.1039/c7ra10533a

Ejemplares similares